These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 1673342)

  • 21. Hypoglycemia-induced suppression of luteinizing hormone (LH) secretion in intact female rhesus macaques: role of vasopressin and endogenous opioids.
    Lado-Abeal J; Clapper JA; Chen Zhu B; Hough CM; Syapin PJ; Norman RL
    Stress; 2002 Jun; 5(2):113-9. PubMed ID: 12186689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of melatonin on hypoglycemia and metoclopramide-stimulated arginine vasopressin secretion in normal men.
    Coiro V; Volpi R; Caffarri G; Capretti L; Marchesi C; Giacalone G; Chiodera P
    Neuropeptides; 1997 Aug; 31(4):323-6. PubMed ID: 9308018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence for a role of opioid peptides in the release of arginine vasopressin in the conscious rat.
    Ishikawa S; Schrier RW
    J Clin Invest; 1982 Mar; 69(3):666-72. PubMed ID: 6174549
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endogenous opioids inhibit oxytocin release during nicotine-stimulated secretion of vasopressin in man.
    Seckl JR; Johnson M; Shakespear C; Lightman SL
    Clin Endocrinol (Oxf); 1988 May; 28(5):509-14. PubMed ID: 3214943
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Naloxone decreases the inhibitory effect of ethanol on the release of arginine-vasopressin induced by physical exercise in man.
    Coiro V; Casti A; Volta E; Melani A; Maffei ML; Rubino P; Vacca P; Saccani-Jotti G; Volpi R; Chiodera P
    J Neural Transm (Vienna); 2009 Sep; 116(9):1065-9. PubMed ID: 19649691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naloxone decreases the inhibitory effect of somatostatin on GH release induced by cigarette smoking in man.
    Coiro V; Volpi R; Stella A; Cataldo S; Giumelli C; Maccanelli F; Araldi A; Chiodera P
    J Neural Transm (Vienna); 2011 Aug; 118(8):1173-5. PubMed ID: 21360300
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of a V1-vasopressin antagonist on ACTH release following vasopressin infusion or insulin-induced hypoglycemia in normal men.
    Hader O; Bähr V; Hensen J; Hofbauer KG; Oelkers WK
    Acta Endocrinol (Copenh); 1990 Dec; 123(6):622-8. PubMed ID: 2178298
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Failure of naloxone to influence plasma growth hormone, prolactin, and cortisol secretions induced by insulin hypoglycemia.
    Wakabayashi I; Demura R; Miki N; Ohmura E; Miyoshi H; Shizume K
    J Clin Endocrinol Metab; 1980 Mar; 50(3):597-9. PubMed ID: 6987258
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of naloxone on the inhibitory effect of melatonin on the release of arginine-vasopressin induced by physical exercise in man.
    Coiro V; Volpi R; Maffei ML; Volta E; Melani A; Chiodera P
    Regul Pept; 2010 Jun; 162(1-3):1-4. PubMed ID: 20346989
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible involvement of endogenous opioid peptides in the inhibition of arginine vasopressin release by gamma-aminobutyric acid in conscious rats.
    Otake K; Kondo K; Oiso Y
    Neuroendocrinology; 1991 Aug; 54(2):170-4. PubMed ID: 1766553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Insulin-induced hypoglycemia, L-dopa and arginine stimulate GH secretion through different mechanisms in man.
    Masuda A; Shibasaki T; Hotta M; Yamauchi N; Ling N; Demura H; Shizume K
    Regul Pept; 1990 Oct; 31(1):53-64. PubMed ID: 2270318
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evidence for endogenous opioid control of vasopressin release in man.
    Lightman SL; Forsling ML
    J Clin Endocrinol Metab; 1980 Mar; 50(3):569-71. PubMed ID: 7358835
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Naloxone increases the angiotensin II stimulated rise of arginine vasopressin and oxytocin secretion in man.
    Coiro V; Chiodera P
    Neuroendocrinology; 1991 Mar; 53(3):209-13. PubMed ID: 2041583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of obesity and weight loss on the arginine vasopressin response to insulin-induced hypoglycaemia.
    Coiro V; Chiodera P
    Clin Endocrinol (Oxf); 1987 Aug; 27(2):253-8. PubMed ID: 3311483
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Somatostatin centrally inhibits vasopressin secretion during haemorrhage.
    Wang XM; Tresham JJ; Congiu M; Coghlan JP; Scoggins BA
    Brain Res; 1987 Dec; 436(1):199-203. PubMed ID: 2891414
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endogenous opioid modulation of pancreatic hormone secretion: studies in dogs.
    Levin ER; Yamada T; Levin S; Mills S
    Metabolism; 1986 Jan; 35(1):59-63. PubMed ID: 2867455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition by dexamethasone of arginine vasopressin and ACTH responses to insulin-induced hypoglycemia and cigarette smoking in normal men.
    Chiodera P; Coiro V
    Acta Endocrinol (Copenh); 1990 Nov; 123(5):487-92. PubMed ID: 2175139
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of naloxone administration on the secretion of corticotropin-releasing hormone, arginine vasopressin, and adrenocorticotropin in unperturbed horses.
    Alexander SL; Irvine CH
    Endocrinology; 1995 Nov; 136(11):5139-47. PubMed ID: 7588252
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lack of effect of bromocriptine and domperidone on arginine-vasopressin response to insulin-induced hypoglycemia in normal men.
    Chiodera P; Coiro V
    Psychoneuroendocrinology; 1987; 12(3):225-30. PubMed ID: 3039562
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Arginine vasopressin and oxytocin responses to insulin-induced hypoglycemia in type 1 (insulin-dependent) diabetes.
    Fisher BM; Baylis PH; Thornton S; Frier BM
    J Clin Endocrinol Metab; 1989 Mar; 68(3):688-92. PubMed ID: 2645315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.